1. Background {#sec150422}
=============

Cost-utility analysis as one of the most frequently used methods of economic evaluation, and it uses the Quality Adjusted Life Years (QALYs) as a generic measure of health outcome. QALYs are unique and exact measures that potentially permit comparisons both within and across all interventions ([@A23556R1]). QALYs capture both the quantity and quality of life years in a single measure of health outcome. The quality component of the QALYs is measured in terms of utility. Utility is a measure to reveal preferences for a given health state that range from 0 (death) to 1 (full health), although a negative value (states perceived to be worse than death) is also possible ([@A23556R2]). There are multiple generic preference-based instruments used to estimate utility values for computing QALYs. The EuroQol (EQ-5D) ([@A23556R3]-[@A23556R5]) and Short Form (SF-6D) ([@A23556R6], [@A23556R7]) are two of the most widely used instruments. Both instruments use a specific descriptive system to classify different health states. Based on the scoring algorithm, which is derived from the general public specifically for each instrument, each classified health state is assigned a value ([@A23556R8]). However, previous studies that have compared these instruments have revealed some differences in their performances ([@A23556R9]). Even though the EQ-5D is widely used, easily administered, and able to detect large differences in health status ([@A23556R10]), its poor performance in detecting small changes in high level of utilities can be of concern ([@A23556R11]). In order to enhance the descriptive richness and sensitivity, the SF-6D measure was therefore developed from the most widely used multi-dimensional SF-36 instrument ([@A23556R7], [@A23556R12]). The main purpose behind its development was to incorporate both the descriptive richness and preference-based properties into a single measure ([@A23556R6]). Meanwhile, previous studies indicated that the SF-6D over-predicted at lower levels of the utility values ([@A23556R6]) and revealed a low sensitivity to change within a lower range of utilities ([@A23556R13]). Moreover, evidence suggests that these two instruments report different utilities and levels of agreements for similar clinical conditions ([@A23556R8], [@A23556R14]-[@A23556R16]). These facts highlight the necessity of more investigations and exercising caution when using these instruments for decision-making.

Breast cancer is the leading cause of cancer death among women and the most frequently diagnosed cancer worldwide ([@A23556R17]). For chronic diseases, such as breast cancer, which have a demonstrated impact on health-related quality of life (HRQL) ([@A23556R18]-[@A23556R20]), integrating HRQL data into the treatment evaluation is essential. Several studies have compared these two instruments in diseases other than breast cancer ([@A23556R8], [@A23556R9], [@A23556R11], [@A23556R13], [@A23556R16]). To the best of our knowledge, no studies have thus far compared the performance of these instruments in Iranian patients with breast cancer, assessing the performance of these instruments in different diseases and sociocultural contexts is of great importance.

2. Objectives {#sec150423}
=============

This study aimed to compare the performance of EQ-5D and SF-6D in different states of breast cancer.

3. Patients and Methods {#sec150427}
=======================

3.1. Design and Recruitment {#sec150424}
---------------------------

This was a cross-sectional study that was approved jointly by the ethics committees of Iran University of Medical Sciences (IUMS) and breast cancer research center (BCRC), ACECR in Tehran, Iran, in December 2012 with code number 631. A total of 163 patients with breast cancer who attended a breast cancer subspecialty clinic affiliated with the BCRC was consecutively recruited between November 2013 and June 2014. The sufficiency of the sample size was based on the minimum value for the intraclass correlation coefficient (ICC) to be treated as good agreement ([@A23556R21]) and also on the method proposed by Walter for determining the sample size for ICC (with α = 0.05 and β = 0.20) ([@A23556R22]). The criteria for inclusion of patients in the study were as follows: confirmed pathological breast cancer providing that the clinical history of the patient was registered in the clinic's database, the patient provided written informed consent, and that there was no comorbidity. Literate patients were asked to self-administer the questionnaire package while they were in the waiting area of the clinic for a physician's visit. This package included the EQ-5D, the SF-36, and questions regarding their demographic characteristics. For illiterate patients, the questionnaire was administered by a trained research assistant. The total sample consisted of patients with different stages of the disease, including the early stages from I - III (both primary breast cancer and loco-regional recurrence) and metastasis. Due to the insufficiency of the data, contralateral breast cancer patients were not included in this study. Patients were assigned to different states based on the date of diagnosis and their pathological stages as recorded in the database. Since the obtained utilities were assumed to be used in economic modeling, the states were constructed based on the predefined states by Lidgren et al. ([@A23556R23]). Accordingly, the first year after primary breast cancer and that after recurrence are defined as "State P" and "State R," respectively. The second and following years after primary breast cancer or recurrence are defined as "State S," while metastatic disease is termed "State M." Further details about the definitions of these states can be found elsewhere ([@A23556R23]).

3.2. Instruments {#sec150425}
----------------

EQ-5D: the EQ-5D ([@A23556R3], [@A23556R5]) is a standard and generic preference-based instrument that was developed by a European group for driving utility values. It has a descriptive classification system with five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each domain has three possible responses (no problems, some problems, and extreme problems). The descriptive system of the EQ-5D offers a total of 243 health states. Originally, these health states were assigned values, using the time trade-off method from a sample of 3395 respondents of the United Kingdom's (UK) general population. Several tariffs from different countries are available. For this study, the UK scoring algorithm was applied. This algorithm yields scores ranging from −0.59 to 1.00, with 0 representing being dead, 1.00 indicating a state of full health, and negative scores indicating health states worse than being dead. The reliability and validity of the EQ-5D have been well documented in different contexts for different diseases ([@A23556R3], [@A23556R11], [@A23556R13]).

SF-6D: the SF-6D ([@A23556R6]), a multidimensional health classification system, is derived from the SF-36, a generic health status instrument that consists of eight scales ([@A23556R12], [@A23556R24]). The SF-6D uses 11 questions from the SF-36 to define the six domains (physical functioning, role limitation, social functioning, pain, mental health, and vitality). Each domain has between four and six levels, resulting in a total of 18000 health states. The health states for SF-6D are assigned values using the algorithm produced by Brazier and colleagues ([@A23556R6], [@A23556R7]). A sample of 249 health states using the standard gamble (SG) method were applied to derive preference weights from a representative sample of the UK population. The utility scores obtained from the SF-6D ranged from 0.29 to 1.00, with 0.29 indicating the worst health state and 1.00 suggesting a fully healthy state other than pet toys. The SF-6D has demonstrated good reliability and validity in different settings ([@A23556R11]).

3.3. Statistical Analysis {#sec150426}
-------------------------

Descriptive statistics (mean, median, inter-quartile range (IQR), and standard deviation (SD)) were used to characterize the study sample. The normality of the utility scores was tested graphically and with the skewness and kurtosis normality test. Due to a skewed distribution of the data, we performed a nonparametric Kruskal-Wallis test to test for differences in utility values between different states for both EQ-5D and SF-6D. In addition, we pooled the entire sample of different states together and assessed the agreement between two instruments by the ICC and Bland-Altman plot. All statistical analyses were performed using STATA 12.0 and MedCal 13.0.6 software.

4. Results {#sec150430}
==========

4.1. Patient Characteristics {#sec150428}
----------------------------

Of the 163 patients who were eligible to participate in the study, two (1.2%) failed to complete the EQ-5D (step 5) and three (1.8%) did not complete the SF-6D. We assessed the characteristics of the failed patients and found that they did not differ from the patients who fully completed the instruments. Therefore, these missing data were supposed to be at random. We performed our analyses based on the 158 patients for whom both the EQ-5D and SF-6D were available. The clinical and demographic characteristics of patients are presented in [Table 1](#tbl38476){ref-type="table"}. The mean age of respondents was 46.7 years. The largest and smallest numbers of patients were in the "state S" (44.9%) and "state R" (9.4%) groups, respectively.

###### Clinical and Demographic Characteristics of Patients with Breast Cancer^[a](#fn41470){ref-type="table-fn"}^

  Characteristics     Values
  ------------------- -------------
  **Entire states**   158 (100)
  **State P**         48 (30.3)
  **State R**         15 (9.4)
  **State S**         71 (44.9)
  **State M**         24 (15.1)
  **Mean age, y**     46.7 (9.97)

^a^Data are represented as No (%), except for age that is represented by mean (SD).

4.2. Instrument Comparisons {#sec150429}
---------------------------

As illustrated in [Table 2](#tbl38477){ref-type="table"}, the mean and median EQ-5D utility scores for total sample were 0.685 and 0.761, respectively. At the same time, the mean SF-6D utility score for the total sample was 0.653, and the median utility score was 0.640. The mean utility scores for different states of the EQ-5D for "state P," "state R," "state S," and "state M," were estimated at 0.674, 0.718, 0.730, and 0.552, respectively. The SF-6D gave the mean utility values of 0.638, 0.677, 0.681, and 0.587 for those states. Moreover, the median for different states and the IQR for the total sample are shown in [Table 2](#tbl38477){ref-type="table"}. [Figure 1](#fig28470){ref-type="fig"} and [2](#fig28471){ref-type="fig"} show the distribution of utility values in the total sample for both EQ-5D and SF-6D measures. It is immediately obvious that the distribution of utility values for the SF-6D was more symmetrical than that for EQ-5D. In addition, compared to SF-6D, the range of utility values for EQ-5D was widely spread. Furthermore, the skewness and kurtosis normality test revealed a skewed distribution (P = 0.001) for EQ-5D, whereas the utility scores for SF-6D were normal (P = 0.115). Both EQ-5D (K-W, P = 0.004) and SF-6D (K-W, P = 0.002) gave significantly different utility scores among different health states. The ICC for two measures was 0.677 (95% CI: 0.558 - 0.764). The Bland-Altman plot used for agreement is presented in [Figure 3](#fig28472){ref-type="fig"}. In general, the pattern of observations indicates that there is better agreement amongst the higher values, and that at higher values," the EQ-5D yields a higher score than the SF-6D, while this relationship reverses at lower values.

###### Utility Scores of Instruments

                     SF-6D   EQ-5D                                                 
  ------------------ ------- --------- --------- ------- ------- ------- --------- -------
  **Total sample**   0.640   0.653     (0.129)   0.120   0.761   0.685   (0.216)   0.327
  **State P**        0.638   0.638     (0.125)   \-      0.761   0.674   (0.201)   \-
  **State R**        0.680   0\. 677   (0.063)   \-      0.761   0.718   (0.139)   \-
  **State S**        0.671   0.681     (0.134)   \-      0.799   0.730   (0.221)   \-
  **State M**        0.581   0.587     (0.130)   \-      0.511   0.552   (0.227)   \-

Abbreviation: IQR, Inter-quartile range.

![Distribution of the EuroQol (EQ-5D) Utility Scores](ircmj-18-05-23556-i001){#fig28470}

![Distribution of the Short Form 6D (SF-6D) Utility Scores](ircmj-18-05-23556-i002){#fig28471}

![Bland-Altman Plots of Agreement between EQ-5D and SF-6D Utilities](ircmj-18-05-23556-i003){#fig28472}

5. Discussion {#sec150431}
=============

Utility indices are the key component of a cost-utility analysis. The instruments which are used to produce utilities should be valid, and using different instruments should not influence the conclusions of an economic evaluation. Therefore, assessing the performance of different utility measures across various interventions and sociocultural contexts is of great importance. We compared the performance of the EQ-5D and the SF-6D in patients with different states of breast cancer. In general, the two instruments were able to discriminate between various states, and they assigned low values to most severe states and also conversely to states with a low severity. Despite the fact that these instruments were primarily developed to measure exactly similar values, we found considerable differences between these instruments. Firstly, the EQ-5D and SF-6D captured different numbers of domains (5 vs. 6), and the vitality domain within the SF-6D has no counterpart domain within the EQ-5D. Secondly, the two instruments revealed considerably different distributions ([Figures 1](#fig28470){ref-type="fig"} and [2](#fig28471){ref-type="fig"}). The EQ-5D was distributed with skewing towards the higher values, which produced a ceiling effect. In contrast, the SF-6D distributed with an approximation to a normal distribution. Due to dissimilar distributions, we compared the median for two measures and, consequently, the differences between the median values exceeded the minimally important difference (MID) ([@A23556R25]) for both instruments. Even though the ICC showed a fair agreement, the Bland-Altman plot represented that a large proportion of differences were exceeded the MID. Furthermore, the agreement was much poorer at lower utility values than the higher utility values. This pattern of distribution was consistent with other studies that revealed poor relationship between two instruments ([@A23556R26], [@A23556R27]). There are a number of reasons for these noticeable differences also, as stated by other authors ([@A23556R26], [@A23556R27]). Because of its high lower boundary, the SF-6D of 0.30 generates a narrower range of utility scores. This leads an underestimation in the changes of utility values for interventions that influence the lower end of the range. Another reason for the different results was the underlying techniques required to derive the utility algorithms. The EQ-5D utility algorithm is based upon the time trade-off (TTO) technique, whereas the SF-6D values were elicited using the standard gamble (SG) technique ([@A23556R5], [@A23556R6]). Some studies have demonstrated higher values for SG in comparison with TTO technique ([@A23556R28], [@A23556R29]).

This study estimated the utility values for different states of breast cancer that can be used in a model based cost-utility analysis and will be a valuable addition to the scientific literature. In addition, this is, to our best knowledge, the first study to report and compare the EQ-5D and SF-6D in an Irani's context in patients with breast cancer. Nevertheless, we compared the performance of two commonly used measures, and there appeared to be statistically and clinically significant differences in the utilities generated by these instruments. Consequently, if these values used as the weightings for QALYs, they would not result in comparable estimates. There are also some limitations to this study, which necessitate exercising caution when using results from this study. Firstly, the scoring algorithms for both instruments were based on a UK population, which may differ from values revealed by the Iranian population. Secondly, even though the patients were recruited consecutively, they were not assigned randomly. Third, the sample size used in the present study was quite small; therefore, further research with large samples will be required to confirm the findings from this study.
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